# OnCo record nct06771622 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06771622/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06771622", "NCT06771622" ;
  schema:name "Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Trastuzumab, Pertuzumab, Oxaliplatin, Capecitabine, Ramucirumab and Bevacizumab in advanced solid tumours, run by FBD Biologics Limited, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06771622/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06771622> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2025-03-13" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/bevacizumab/> .